Repurposed Drugs for Prostate Cancer
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology
This article reviews methodology of TSR and critically discusses key TSR studies. In addition, potential conceptual and computational improvements of this novel methodology are discussed as well as its current and possible future application in precision oncology trials. (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities
It has long been recognized that combining radiotherapy with cytotoxic drugs such as cisplatin can improve efficacy. However, while concurrent chemoradiotherapy improves patient outcomes, it comes at costs of increased toxicity. A tremendous opportunity remains to investigate drug combinations in the clinical setting that might increase the benefits of radiation without additional toxicity. This chapter highlights opportunities to apply repurposing of drugs along with a mechanistic understanding of radiation effects on cancer and normal tissue to discover new therapy-modifying drugs and help rapidly translate them to the c...
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Perioperative Therapies—Using Repurposed Drugs to Improve Cancer Surgery Outcomes
Discussion
The perioperative setting is not as well established as the neoadjuvant and adjuvant settings, making identification of relevant research and clinical trials difficult. Despite the potential benefits of such interventions, there is a need for more well-designed clinical trials, additional research, and biomarkers of response. (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Repurposing Food and Drug Administration–Approved Drugs to Promote Antitumor Immunity
There has been a major resurgence of interest in immune-based approaches to treat cancer, based largely on the success of checkpoint inhibitors (anti–cytotoxic T-lymphocyte–associated antigen 4, anti–programmed cell death 1, and anti–programmed cell death ligand 1 antibodies) in several malignancies. However, not all tumors respond to checkpoint therapy, and there is clearly a need for additional approaches for enhancing tumor immunity. We summarize the critical elements necessary for mounting an efficacious T-cell response to a tumor. We cite drugs approved by the Food and Drug Administration for no-cancer indicat...
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Identifying Drug Repurposing Opportunities in Oncology
The never-ending explosion in the cost of new oncology drugs is reducing in many countries the access to the most recent, effective anticancer therapies and represents a significant obstacle to the design and realization of combinatorial trials. Already approved, anticancer and nonanticancer drugs can be considered for in silico, preclinical, and clinical repurposing approaches and offer the significant advantages of a potentially cheaper, faster, and safer validation. This review discusses recent advances and challenges in the field. (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Introduction: Repurposed Drugs: Teaching an Old Dog New Tricks
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Multiplatform Molecular Profiling: A Precision Medicine Victory Built on Cytotoxic Chemotherapy
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer: Data of a Pooled Analysis
Conclusions
We conclude that pretreated cancer patients can benefit from incorporation of molecular profiling, as demonstrated by not only an increase of the PFS ratio but also PFS. Further randomized trials in specific tumor subtypes may help establish specific patient populations who might benefit most from MMP guidance. (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Original Articles Source Type: research
Smoldering Multiple Myeloma: To Treat or Not to Treat
Smoldering multiple myeloma (SMM) is an asymptomatic, intermediate stage positioned between the plasma cell disorders of monoclonal gammopathy of undermined significance and overt multiple myeloma (MM). Although the patients with SMM have a higher risk of progression to MM in comparison to their counterparts with monoclonal gammopathy of undermined significance, their clinical course can be highly variable. The standard of care for SMM, irrespective of the risk status, continues to be observation due to paucity of high-level evidence demonstrating survival or quality-of-life benefit with early intervention. With the expand...
Source: The Cancer Journal - January 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Targeted Management Strategies in Multiple Myeloma
There has been a paradigm shift in the treatment of myeloma triggered by intense exploration of the disease biology to understand the basis of disease development and progression and the evolution of newly diagnosed myeloma to a multidrug refractory state that is associated with poor survival. These studies have in turn informed us of potential therapeutic strategies in our ongoing effort to cure this disease, or at a minimum convert it into a chronic disease. Given the clonal evolution that leads to development of drug resistance and treatment failure, identification of specific genetic abnormalities and approaches to tar...
Source: The Cancer Journal - January 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Risk-Based Therapeutic Strategies
Although therapeutic strategies have been adapted to age and comorbidities of myeloma patients for a long time, all patients currently experiment the same treatment whatever their genomic risk. However, high-risk patients should benefit right now from the most efficient drugs combinations. Herein, we review and discuss how to optimally define risk to adapt treatment and why a modern multiparametric definition of genomic risk is urgently needed. Minimal residual disease status will probably also take a growing place in patient's management, including in treatment adaptation. We also discuss how next-generation sequencing wi...
Source: The Cancer Journal - January 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Novel Agents in Multiple Myeloma
The therapeutic landscape of multiple myeloma (MM) has dramatically changed in the last 15 years with the advent of immunomodulatory drugs and proteasome inhibitors. However, majority of MM patients relapse, and new therapies are needed. Various agents with diverse mechanisms of action and distinct targets, including cellular therapies, monoclonal antibodies, and small molecules, are currently under investigation. In this review, we report novel drugs recently approved or under advanced investigation that will likely be incorporated in the future as new standard for MM treatment, focusing on their mechanisms of action, cel...
Source: The Cancer Journal - January 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Cellular Immunotherapy for Multiple Myeloma
Cellular immunotherapy for myeloma has the unique potential both to potently kill the malignant clone and to evoke a memory response to protect from relapse. Understanding the complex interactions between the malignant clone and the microenvironment that promote immune escape is critical to evoke effective antimyeloma immunity. Tremendous progress has been made in the area of cancer vaccines and adoptive T-cell therapy in recent years. Careful study of the mechanisms of response and of immune escape will be critical to developing novel combination therapies and ultimately to improve outcomes for patients with myeloma. (Sou...
Source: The Cancer Journal - January 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Are 4-Drug Regimens Here to Stay? Role in Induction and Salvage Therapies
With 10 novel therapies approved across the decade, the multiple myeloma (MM) treatment paradigm continues to evolve in breadth and complexity. The current gestalt of the day has been the emergence of data to support 3-drug combinations over their 2-drug counterparts. Current guidelines and consensus statements support this approach. With the recent incorporation of monoclonal antibodies into the fray of myeloma therapy, we have begun to ask what the roles of 4-drug combinations are in both the upfront and the relapsed and refractory settings. The recent approval of daratumumab in combination with bortezomib, melphalan, an...
Source: The Cancer Journal - January 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
